Unknown EARLY_PHASE1 INTERVENTIONAL 2-arm NCT05435755

Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.

The Precise Transplantation of Human Amniotic Epithelial Stem Cells Into the Ventricle Through Surgical Robot in the Treatment of Parkinson's Disease.

Sponsor: Shanghai East Hospital

Conditions Parkinson's Disease

Interventions hAESCs treatment placebo (saline)

Updated 5 times since 2022 Last updated: Oct 27, 2022 Started: Dec 2, 2022 Primary completion: Jul 30, 2023 Completion: Aug 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Parkinson's Disease, this trial is ongoing. The trial is conducted by Shanghai East Hospital and has accumulated 5 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Nov 2024 — Present [monthly]

Unknown EARLY_PHASE1

Status: Not Yet Recruiting → Unknown
Sep 2024 — Nov 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1
Nov 2022 — Jul 2024 [monthly]

Not Yet Recruiting EARLY_PHASE1
Jul 2022 — Nov 2022 [monthly]

Not Yet Recruiting EARLY_PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai East Hospital
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Data source: Shanghai East Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China